ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 19.16
(-2.15%)
SEK 19.16
(-2.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -91.4 Million SEK | 22.94% |
| 2022 | -118.6 Million SEK | -170.02% |
| 2021 | -43.92 Million SEK | -38.51% |
| 2020 | -31.71 Million SEK | -89.86% |
| 2019 | -16.7 Million SEK | 0.71% |
| 2018 | -16.82 Million SEK | -71.04% |
| 2017 | -9.83 Million SEK | -15.19% |
| 2016 | -8.53 Million SEK | -1.18% |
| 2015 | -8.43 Million SEK | -3121.09% |
| 2014 | 279.3 Thousand SEK | -59.44% |
| 2013 | 688.66 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -12.85 Million SEK | 27.86% |
| 2024 Q2 | 2.53 Million SEK | 119.74% |
| 2023 Q2 | -30.03 Million SEK | -14.18% |
| 2023 Q4 | -17.81 Million SEK | 18.37% |
| 2023 FY | -91.4 Million SEK | 22.94% |
| 2023 Q3 | -21.82 Million SEK | 27.34% |
| 2023 Q1 | -26.3 Million SEK | 45.79% |
| 2022 Q3 | -30.7 Million SEK | -20.23% |
| 2022 FY | -118.6 Million SEK | -170.02% |
| 2022 Q4 | -48.53 Million SEK | -58.08% |
| 2022 Q2 | -25.53 Million SEK | -84.55% |
| 2022 Q1 | -13.83 Million SEK | 3.38% |
| 2021 Q3 | -9.38 Million SEK | -3.46% |
| 2021 Q1 | -11.15 Million SEK | 35.71% |
| 2021 Q2 | -9.06 Million SEK | 18.72% |
| 2021 FY | -43.92 Million SEK | -38.51% |
| 2021 Q4 | -14.32 Million SEK | -52.63% |
| 2020 Q2 | -4.23 Million SEK | 19.01% |
| 2020 Q1 | -5.23 Million SEK | 17.47% |
| 2020 Q3 | -4.88 Million SEK | -15.29% |
| 2020 FY | -31.71 Million SEK | -89.86% |
| 2020 Q4 | -17.35 Million SEK | -255.08% |
| 2019 Q4 | -6.34 Million SEK | -115.42% |
| 2019 Q1 | -4.34 Million SEK | 22.27% |
| 2019 FY | -16.7 Million SEK | 0.71% |
| 2019 Q3 | -2.94 Million SEK | 4.29% |
| 2019 Q2 | -3.07 Million SEK | 29.14% |
| 2018 Q1 | -3.21 Million SEK | -2.62% |
| 2018 FY | -16.82 Million SEK | -71.04% |
| 2018 Q3 | -4.69 Million SEK | -41.42% |
| 2018 Q2 | -3.32 Million SEK | -3.26% |
| 2018 Q4 | -5.58 Million SEK | -18.88% |
| 2017 Q1 | -1.1 Million SEK | 73.28% |
| 2017 Q3 | -2.95 Million SEK | -12.1% |
| 2017 Q4 | -3.13 Million SEK | -6.09% |
| 2017 FY | -9.83 Million SEK | -15.19% |
| 2017 Q2 | -2.63 Million SEK | -137.69% |
| 2016 Q4 | -4.15 Million SEK | -57.44% |
| 2016 Q2 | -1.75 Million SEK | 79.48% |
| 2016 FY | -8.53 Million SEK | -1.18% |
| 2016 Q1 | -8.53 Million SEK | 0.0% |
| 2016 Q3 | -2.63 Million SEK | -50.46% |
| 2015 FY | -8.43 Million SEK | -3121.09% |
| 2014 FY | 279.3 Thousand SEK | -59.44% |
| 2013 FY | 688.66 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -454.618% |
| Amniotics AB (publ) | -30.87 Million SEK | -196.084% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -612.512% |
| BioArctic AB (publ) | 229.24 Million SEK | 139.87% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 80.394% |
| Camurus AB (publ) | 431.44 Million SEK | 121.185% |
| Cantargia AB (publ) | -280.02 Million SEK | 67.36% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -333.365% |
| Genovis AB (publ.) | 61.5 Million SEK | 248.62% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 19.345% |
| Mendus AB (publ) | -101.61 Million SEK | 10.055% |
| Kancera AB (publ) | -64.88 Million SEK | -40.857% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1797.011% |
| LIDDS AB (publ) | -40.2 Million SEK | -127.332% |
| Lipum AB (publ) | -37.17 Million SEK | -145.847% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -653.636% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 851.097% |
| NextCell Pharma AB | -41.95 Million SEK | -117.83% |
| OncoZenge AB (publ) | -15.9 Million SEK | -474.777% |
| Saniona AB (publ) | -95.81 Million SEK | 4.602% |
| Simris Alg AB (publ) | -37.3 Million SEK | -145.01% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 70.605% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 76.453% |
| Xintela AB (publ) | -54.08 Million SEK | -69.001% |
| Ziccum AB (publ) | -21.41 Million SEK | -326.868% |
| AcouSort AB (publ) | -17.08 Million SEK | -434.853% |
| Active Biotech AB (publ) | -45.8 Million SEK | -99.566% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -457.392% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -410.706% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -146.557% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 49.128% |
| CombiGene AB (publ) | -35.66 Million SEK | -156.274% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 39.808% |
| Intervacc AB (publ) | -102.85 Million SEK | 11.133% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 63.232% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -20767.808% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -453.174% |
| Corline Biomedical AB | -1.8 Million SEK | -4952.57% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 48.605% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -60.858% |
| Aptahem AB (publ) | -11.11 Million SEK | -722.479% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 25.731% |
| Fluicell AB (publ) | -26.55 Million SEK | -244.208% |
| Biovica International AB (publ) | -124.82 Million SEK | 26.776% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -116.472% |
| Abliva AB (publ) | -95.5 Million SEK | 4.301% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 72.04% |
| 2cureX AB (publ) | -32.51 Million SEK | -181.078% |
| I-Tech AB | 20.2 Million SEK | 552.413% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 89.011% |
| Cyxone AB (publ) | -22.98 Million SEK | -297.586% |
| Biosergen AB | -27.03 Million SEK | -238.059% |
| Nanologica AB (publ) | -75.15 Million SEK | -21.613% |
| SynAct Pharma AB | -215.81 Million SEK | 57.647% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -107.475% |
| BioInvent International AB (publ) | -330.3 Million SEK | 72.328% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -285.057% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 63.309% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -820.452% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 16.367% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -682.677% |